It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CZMWF’s FA Score shows that 1 FA rating(s) are green whileXAIR’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CZMWF’s TA Score shows that 2 TA indicator(s) are bullish while XAIR’s TA Score has 4 bullish TA indicator(s).
CZMWF (@Pharmaceuticals: Other) experienced а -12.92% price change this week, while XAIR (@Medical/Nursing Services) price change was +4.90% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +2.26%. For the same industry, the average monthly price growth was -2.99%, and the average quarterly price growth was +3.27%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.72%. For the same industry, the average monthly price growth was +0.71%, and the average quarterly price growth was +4.00%.
XAIR is expected to report earnings on Nov 17, 2025.
Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical/Nursing Services (-1.72% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
CZMWF | XAIR | CZMWF / XAIR | |
Capitalization | 4.4B | 13.9M | 31,647% |
EBITDA | 389M | N/A | - |
Gain YTD | 1.559 | -58.159 | -3% |
P/E Ratio | 24.47 | N/A | - |
Revenue | 2.17B | N/A | - |
Total Cash | 51.5M | N/A | - |
Total Debt | 147M | 11.7M | 1,256% |
CZMWF | XAIR | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 94 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 29 Undervalued | 31 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 78 | 100 | |
PRICE GROWTH RATING 1..100 | 89 | 94 | |
P/E GROWTH RATING 1..100 | 64 | 100 | |
SEASONALITY SCORE 1..100 | 50 | 10 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CZMWF's Valuation (29) in the null industry is in the same range as XAIR (31). This means that CZMWF’s stock grew similarly to XAIR’s over the last 12 months.
CZMWF's Profit vs Risk Rating (100) in the null industry is in the same range as XAIR (100). This means that CZMWF’s stock grew similarly to XAIR’s over the last 12 months.
CZMWF's SMR Rating (78) in the null industry is in the same range as XAIR (100). This means that CZMWF’s stock grew similarly to XAIR’s over the last 12 months.
CZMWF's Price Growth Rating (89) in the null industry is in the same range as XAIR (94). This means that CZMWF’s stock grew similarly to XAIR’s over the last 12 months.
CZMWF's P/E Growth Rating (64) in the null industry is somewhat better than the same rating for XAIR (100). This means that CZMWF’s stock grew somewhat faster than XAIR’s over the last 12 months.
CZMWF | XAIR | |
---|---|---|
RSI ODDS (%) | 4 days ago54% | 4 days ago83% |
Stochastic ODDS (%) | N/A | 4 days ago85% |
Momentum ODDS (%) | 4 days ago57% | 4 days ago88% |
MACD ODDS (%) | N/A | 4 days ago85% |
TrendWeek ODDS (%) | 4 days ago56% | 4 days ago82% |
TrendMonth ODDS (%) | 4 days ago57% | 4 days ago89% |
Advances ODDS (%) | N/A | 4 days ago82% |
Declines ODDS (%) | N/A | 11 days ago87% |
BollingerBands ODDS (%) | 4 days ago52% | 4 days ago90% |
Aroon ODDS (%) | 4 days ago56% | 4 days ago88% |
A.I.dvisor indicates that over the last year, CZMWF has been loosely correlated with CZMWY. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CZMWF jumps, then CZMWY could also see price increases.
Ticker / NAME | Correlation To CZMWF | 1D Price Change % | ||
---|---|---|---|---|
CZMWF | 100% | -8.26% | ||
CZMWY - CZMWF | 46% Loosely correlated | -0.22% | ||
XAIR - CZMWF | 31% Poorly correlated | +5.63% | ||
SHWGY - CZMWF | 26% Poorly correlated | N/A | ||
ECIA - CZMWF | 23% Poorly correlated | N/A | ||
IRME - CZMWF | 21% Poorly correlated | -23.78% | ||
More |
A.I.dvisor indicates that over the last year, XAIR has been loosely correlated with CZMWY. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if XAIR jumps, then CZMWY could also see price increases.
Ticker / NAME | Correlation To XAIR | 1D Price Change % | ||
---|---|---|---|---|
XAIR | 100% | +5.63% | ||
CZMWY - XAIR | 38% Loosely correlated | -0.22% | ||
SHWGY - XAIR | 36% Loosely correlated | N/A | ||
RBOT - XAIR | 32% Poorly correlated | +4.48% | ||
CZMWF - XAIR | 31% Poorly correlated | -8.26% | ||
IRME - XAIR | 27% Poorly correlated | -23.78% | ||
More |